ArticleScientific reports2019
Identification and characterization of phage protein and its activity against two strains of multidrug-resistant Pseudomonas aeruginosa.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Efficacy of phage therapy in Diabetic Foot Ulcers (DFUs): a systematic review.BMC infectious diseases · 2025Pooled it
- Lytic activity of F8-like phage φSPM-1 against One Health lineages of carbapenem-resistant Pseudomonas aeruginosa.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Regenerative Microbiology: Harnessing Bacterial Antagonism and Spatiotemporal Signaling for Diabetic Wound Repair.Smart medicine · 2026Review
- Phage-encoded protein PavP modulates Pseudomonas aeruginosa virulence by dual inhibition of growth and pathogenic traits.Biology direct · 2025Article
- Isolation and Characterization of A Novel Pbunavirus with Promising Antibiofilm Activity Against Pseudomonas Aeruginosa.Current microbiology · 2025Article
- OvercomingAntibiotics (Basel, Switzerland) · 2025Review
- Characterization and genomic analysis of PA-56Heliyon · 2024Article
- Article
- Chemical-Biology and Metabolomics Studies in Phage-Host Interactions.Advances in experimental medicine and biology · 2023Article
- Proteomics approaches: A review regarding an importance of proteome analyses in understanding the pathogens and diseases.Frontiers in veterinary science · 2022Review
- Bacteriophage-Mediated Control of Biofilm: A Promising New Dawn for the Future.Frontiers in microbiology · 2022Review
- Pseudo-188D: Phage Protein Prediction Based on a Model of Pseudo-188D.Frontiers in genetics · 2021Article
- Bacteriophage Treatment: Critical Evaluation of Its Application on World Health Organization Priority Pathogens.Viruses · 2020Review
- Biological challenges of phage therapy and proposed solutions: a literature review.Expert review of anti-infective therapy · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pseudomonas aeruginosa is an opportunistic pathogen with a capacity to develop antibiotic resistance, which underlies a larger proportion of hospital-acquired infections and higher morbidity and mortality, compared to other bacterial infections. Effective novel approaches for treatment of infections induced by this pathogen are therefore necessary. Phage therapy represents a promising alternative solution to eradicate antibiotic-resistant pathogens. Here, we investigated phage protein efficacy against multi-drug resistant (MDR) P. aeruginosa PAR21 and PAR50 strains isolated from diabetic foot ulcer patients. The results obtained using spot assay, zymography, spectrophotometry and scanning electron microscopy at low voltage (SEM-LV) indicate that the phage protein, PA-PP, exerts activity against P. aeruginosa PAR50 while having no impact on the PAR21 strain. Using LC-MS-MS/MS and comparative analysis of the peptide molecular mass with the protein sequence database, PA-PP was identified as a member of the serine protease family, a result corroborated by its ability to digest casein. We additionally showed a capacity of PA-PP to digest porin protein on the bacterial outer membrane (OM). Moreover, synergistic activity between PA-PP protein and piperacillin led to higher sensitivity of bacterial cells to this antibiotic. Our collective findings suggest that PA-PP targets porin protein on PAR50 OM, thereby increasing its sensitivity to specific antibiotics. The adverse effects observed on bacterial cells using SEM-LV suggest further roles of this protein that remain to be established.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.